KR20240040088A - R-스폰딘 단백질의 재조합 변이체 및 그의 용도 - Google Patents

R-스폰딘 단백질의 재조합 변이체 및 그의 용도 Download PDF

Info

Publication number
KR20240040088A
KR20240040088A KR1020247005290A KR20247005290A KR20240040088A KR 20240040088 A KR20240040088 A KR 20240040088A KR 1020247005290 A KR1020247005290 A KR 1020247005290A KR 20247005290 A KR20247005290 A KR 20247005290A KR 20240040088 A KR20240040088 A KR 20240040088A
Authority
KR
South Korea
Prior art keywords
seq
variant
rspol
domain
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247005290A
Other languages
English (en)
Korean (ko)
Inventor
파트릭 콜롬바트
파올로 보티
Original Assignee
디오젠엑스
상뜨르 나쇼날 드 라 러쉐르쉬 샹띠피끄
유니베르시테 코트 다쥐르
인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 디오젠엑스, 상뜨르 나쇼날 드 라 러쉐르쉬 샹띠피끄, 유니베르시테 코트 다쥐르, 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) filed Critical 디오젠엑스
Publication of KR20240040088A publication Critical patent/KR20240040088A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020247005290A 2021-07-15 2022-07-15 R-스폰딘 단백질의 재조합 변이체 및 그의 용도 Pending KR20240040088A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP21305993 2021-07-15
EP21305993.4 2021-07-15
EP22305328.1 2022-03-18
EP22305328 2022-03-18
PCT/EP2022/069925 WO2023285686A2 (en) 2021-07-15 2022-07-15 Recombinant variants of r-spondin proteins and their use

Publications (1)

Publication Number Publication Date
KR20240040088A true KR20240040088A (ko) 2024-03-27

Family

ID=82799950

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247005290A Pending KR20240040088A (ko) 2021-07-15 2022-07-15 R-스폰딘 단백질의 재조합 변이체 및 그의 용도

Country Status (9)

Country Link
US (2) US20240383952A1 (https=)
EP (1) EP4370535A2 (https=)
JP (1) JP2024526356A (https=)
KR (1) KR20240040088A (https=)
AU (1) AU2022311529A1 (https=)
CA (1) CA3225626A1 (https=)
IL (1) IL310154A (https=)
MX (1) MX2024000757A (https=)
WO (1) WO2023285686A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230241161A1 (en) * 2020-01-10 2023-08-03 Inserm (Institutnationaldelasanteetdelarecherchemedicale) Rspo1 proteins and their use
CN120813594A (zh) * 2023-01-19 2025-10-17 迪奥根克斯公司 R-spondin蛋白的重组变体及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
US8377653B2 (en) 2005-02-11 2013-02-19 Icosagen Cell Factory Oü Viral expression plasmids for production of proteins, antibodies, enzymes, virus-like particles and for use in cell-based assays
US7790446B2 (en) 2005-02-11 2010-09-07 Kosagen Cell Factory Oü Vectors, cell lines and their use in obtaining extended episomal maintenance replication of hybrid plasmids and expression of gene products
AU2013204484B2 (en) * 2011-07-15 2016-05-12 Oncomed Pharmaceuticals, Inc. RSPO binding agents and uses thereof
WO2013049375A2 (en) * 2011-09-28 2013-04-04 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for modulating beta cell proliferation
US9783784B2 (en) * 2013-01-04 2017-10-10 City Of Hope Methods for establishing and improving the survival of a population of pancreatic progenitor or stem cells
US9777052B2 (en) * 2014-12-02 2017-10-03 The Board Of Regents Of The University Of Oklahoma R-spondin variants, compositions, and methods of use
WO2018140821A1 (en) * 2017-01-26 2018-08-02 Surrozen, Inc. Tissue-specific wnt signal enhancing molecules and uses thereof
JP2021020900A (ja) * 2019-07-29 2021-02-18 国立大学法人北海道大学 糖代謝異常改善剤

Also Published As

Publication number Publication date
WO2023285686A3 (en) 2023-03-02
EP4370535A2 (en) 2024-05-22
CA3225626A1 (en) 2023-01-19
US20230340044A1 (en) 2023-10-26
JP2024526356A (ja) 2024-07-17
IL310154A (en) 2024-03-01
US20240383952A1 (en) 2024-11-21
MX2024000757A (es) 2024-04-18
WO2023285686A2 (en) 2023-01-19
AU2022311529A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
KR101993714B1 (ko) 대사 장애를 치료하는데 이용하기 위한 조성물과 방법
CN102143758B (zh) Fgf21突变体及其用途
CN105837680A (zh) 治疗fgf21相关的病症的方法
AU2016346870A1 (en) Dual function proteins and pharmaceutical composition comprising same
TW201420606A (zh) 同源二聚體蛋白
JP2010075189A (ja) 分泌及び膜貫通ポリペプチドとそれをコードする核酸
US20180280474A1 (en) Treatment of bile acid disorders
US20230340044A1 (en) Recombinant variants of r-spondin proteins and their use
JP2026021430A (ja) Ｒｓｐｏ１タンパク質およびその使用
US20110117082A1 (en) Soluble Tumor Necrosis Factor Receptor Mutant
KR20250148592A (ko) R-스폰딘 단백질의 재조합 변이체 및 그의 용도
CN117980323A (zh) R-spondin蛋白的重组变体及其用途
CN115073607A (zh) Tnfr2与baff受体的融合蛋白

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20240215

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)